DNA Biomedical Solutions Ltd. (TASE: DNA) subsidiary Entera Bio Ltd. today announced success in a Phase I clinical trial of its treatment for osteoporosis.
12 healthy patients participated in the safety trial. There were no unusual side effects of changes in heart and liver function, or in metabolism. The drug is based on a known intravenous osteoporosis drug, which has $830 million in annual sales. Entera is developing an oral tablet form of the drug.
The current trial provided no results about the efficacy or absorption rate of the drug, for which another Phase I clinical trial is needed.
Israeli drug development company Transpharma Inc. and pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) are also developing oral treatments for osteoporosis.
DNA's share price rose 4.6% today to NIS 0.16, giving a market cap of NIS 25 million,.
Published by Globes [online], Israel business news - www.globes-online.com - on September 19, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011